Go back

Biotech takeover probed for potentially breaking EU rules

US genomics giant Illumina acquired cancer detection company while $8 billion deal was under review

The European Commission has opened an investigation into actions taken by the US-based genomics company Illumina, after the company announced it had acquired a cancer detection company without waiting for EU approval.

It comes as genetic testing and tailoring of medical treatments to a person’s individual genetic profile is gaining increasing importance for the treatment of diseases with genetic factors, including cancer.

This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Pivot-RP users can log in and view the article via this link.